Mafoprazine is an
antipsychotic of the phenylpiperazine class which is used in
veterinary medicine.[1] Intramuscular injections of mafoprazine mesylate are used for the sedation of pigs either on its own,[2] or in combination with sodium pentobarbital[3] or thiopental.[4]
It demonstrates activity as a D2 dopamine receptor antagonist, an α1 adrenergic receptor antagonist, and an α2 adrenergic receptor agonist.[5]
The affinity of mafoprazine for D2 dopamine receptors is 6 and 16 times lower than that of chlorpromazine and haloperidol, respectively, but 2 times higher than that of azaperone.[5]
The Ki for various receptors was determined using rat neuronal receptor binding assays.[citation needed]
History
Mafoprazine was first synthesized in 1988.[5] It is sold as Mafropan® by DS Pharma Animal Health Co. Ltd., Osaka, Japan.